title: Advances in the treatment of reactions in leprosy.
abstract: Morbidity in leprosy is almost always due to reactions. Similarly, to a great extent, deformities in leprosy are the consequence of reactions occurring both in borderline patients (type 1 or reversal reactions) and in lepromatous patients (type 2 or ENL reactions). Over the last three decades, work has centred around finding who are prone to getting the reactions, identifying the risk factors and improving the management of reactions in order to alleviate quickly the suffering and prevent and reverse nerve damage consequent to reactions. Though several new drugs have been tried and found somewhat useful, corticosteroids and thalidomide continue to be the mainstay in the management of leprosy reactions. A brief review of the current understanding is presented.
authors: National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Taj Ganj, Agra.
authors: B K
authors: BK
authors: Girdhar
authors: A
authors: A
authors: Girdhar
authors: J K
authors: JK
authors: Chakma
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D004893:Erythema Nodosum / Q000188:drug therapy*; D006801:Humans; D015440:Leprosy, Lepromatous / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D013792:Thalidomide